Lyell Immunopharma, Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 3/100
What the filing says
CEO Lynn Seely and CFO Smital Shah certified the June 30, 2026 10-Q filing pursuant to SOX 302 and 906. Both officers attested to the accuracy of financial statements, adequacy of disclosure controls and internal controls, and absence of material weaknesses or fraud. No operational, financial, or strategic changes disclosed.
Why this rating
Routine mandatory SOX certifications; boilerplate compliance document with no material business events, transactions, or financial changes reported.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.